HDT Bio Advances CCHF Vaccine Into Phase 1 Trial
Seattle, Washington, USA – May 21, 2026 HDT Bio and The University of Texas Medical Branch (UTMB) have received...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Seattle, Washington, USA – May 21, 2026 HDT Bio and The University of Texas Medical Branch (UTMB) have received...
SEATTLE, Sept. 19, 2025 – HDT Bio Corporation has announced that the U.S. Food and Drug Administration (FDA) has...
